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Graphical abstract 
 
A combined AUROC classifying patients with NAFLD cirrhosis and healthy control subjects 
 
Lay Summary 
Breath malodor in failing liver is well known since the ancient Greeks. Analytical chemistry has 
provided us an insight into ubiquitous volatile organic compounds in liver and other diseases. 
This has vastly improved our understanding of mechanistic processes of liver damage. Our study 
aims to identify volatile organic compounds which are specific to nonalcoholic fatty liver disease 
which can be exploited for rapid diagnostics.  
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Abstract 
Background: Analysis of volatile organic compounds (VOCs) in exhaled breath, ‘volatomics’, 
provides opportunities for non-invasive biomarker discovery and novel mechanistic insights into 
a variety of diseases.  
Aim: The purpose of this pilot study was to compare breath VOCs in an initial cohort of non-
alcoholic fatty liver disease (NAFLD) patients and healthy controls. 
Methods: Breath samples were collected from 15 participants with Child-Pugh Class A NAFLD 
cirrhosis, 14 with non-cirrhotic NAFLD and 14 healthy volunteers. Exhaled breath samples were 
collected using an established methodology and VOC profiles were analysed by gas 
chromatography-mass spectrometry. The levels of 19 VOCs previously associated with cirrhosis 
were assessed. Peaks of the VOCs were confirmed and integrated using Xcalibur® software, 
normalized to an internal standard. Receiver Operating Characteristic (ROC) curves were used to 
determine the diagnostic accuracy of candidate VOCs. 
Results: Terpinene, dimethyl sulfide (DMS) and D-limonene provided the highest predictive 
accuracy to discriminate between study groups. Combining DMS with D-limonene led to even 
better discrimination of NAFLD cirrhosis from healthy volunteers (AUROC 0.98, 95% 
confidence interval (CI) 0.93 -1.00, p<0.001) and NAFLD cirrhosis from non-cirrhotic NAFLD 
(AUROC 0.91, 95% CI 0.82 – 1.00, p<0.001). Breath terpinene concentrations discriminated 
between non-cirrhotic NAFLD and healthy volunteers (AUROC 0.84, 95% CI 0.68 – 0.99, 
p=0.002). 
Conclusion: Breath terpinene, dimethyl sulfide and D-limonene are potentially useful volatomic 
markers for stratifying NAFLD; and a two-stage approach allows differentiation of non-cirrhotic 
and cirrhotic patients. These observations require validation in a larger NAFLD population. 
(ClinicalTrials.gov Identifier: NCT02950610) 
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) has emerged as the leading cause of chronic liver 
disease worldwide affecting up to 25% of the global population. Its prevalence is expected to 
escalate in parallel with the inexorable rise of obesity and diabetes. It is estimated that nearly 35% 
among those with steatosis will progress to non-alcoholic steatohepatitis (NASH) and, in turn, a 
considerable proportion of those with NASH will advance insidiously to advanced liver disease. 
The severity of hepatic fibrosis has been shown to correlate with all-cause and disease-specific 
mortality in NAFLD[1]. 
Given the potential burden associated with NAFLD, identifying those at high risk of adverse 
outcomes is crucial. Various imaging techniques and biomarkers have been employed to monitor 
NAFLD progression, but none can match the sensitivity and specificity achieved with a 
percutaneous liver biopsy for detection of early stages of liver disease. However, liver biopsy is 
invasive, prone to sampling error and impractical for disease monitoring[2]. Thus, there is a need 
to develop a sensitive, specific and non-invasive diagnostic tool that can accurately characterize 
patients across the entire spectrum of NAFLD.  
In recent years, several studies have explored the use of volatile organic compounds (VOCs) in 
exhaled breath as a non-invasive diagnostic tool in chronic liver disease[3-8]. The underpinning 
concept is that perturbed metabolic pathways can alter the pattern of breath VOC composition. 
An example commonly encountered in a clinical setting is fetor hepaticus that can occur with 
metabolic derangements in cirrhosis. Similarly, NAFLD is associated with a myriad of metabolic 
changes that can influence the composition and concentration of VOCs. Studies have shown 
changes in VOC composition in obese individuals with NAFLD, however correlations with the 
different stages of NAFLD have not been established[4]. Alterations in gut microbiota have 
been shown to contribute to the pathogenesis of NAFLD through metabolic mediators[9]. More 
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recently, a mechanistic study implicated high-alcohol-producing Klebsiella pneumoniae (so called 
‘auto-brewery’) as a potential causative factor in some patients with NAFLD[10]. 
In this pilot study, we examined the pattern of exhaled breath VOCs in patients with cirrhosis 
and non-cirrhotic NAFLD to identify specific biomarker signals with potential utility for the 
stratification of NAFLD.  
 
METHODS 
Study population 
This study was conducted as a substudy of a larger study: Breath analysis using an electronic 
nose in non-alcoholic fatty liver disease (‘BEN’; ClinicalTrials.gov Identifier: NCT02950610), a 
single-centre prospective observational study which aimed to examine exhaled VOC patterns in 
NAFLD using an electronic nose (eNose). Of the total 90 participants, exhaled breath for gas 
chromatography mass spectrometry (GC-MS) was collected from the first 45 consecutive 
participants. This included 30 NAFLD participants with or without cirrhosis (based on 
histological or clinical criteria) and 15 healthy volunteer controls.  
The sample size was based on the following consideration: if molecular compounds are to be 
used in clinical practice, their association should be considerable. We defined the association to 
be potentially useful if the correlation coefficient was larger than 0.6/0.7. For correlations to be 
statistically significant (p<0.05) with 80% power, approximately 15 participants in each group 
were required. Due to contamination issues, one sample each from the non-cirrhotic NAFLD 
and healthy volunteer groups was excluded. Male and female adult participants were recruited 
from the liver outpatient clinics at the Royal Infirmary of Edinburgh (Edinburgh, UK) between 
March 2016 and February 2017. Exclusion criteria were: known respiratory disease, severe 
obesity (body mass index (BMI) >40), use of antibiotics for preceding 4 weeks, ongoing alcohol 
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use of more than 21 units for men and 14 units for women, inability to give informed consent, 
and NAFLD cirrhosis with Child-Pugh score >7.  
Participants with NAFLD were divided into: NAFLD without cirrhosis or NAFLD Child-Pugh 
Class A cirrhosis. This was based on the most recent liver biopsy and/or gastroscopy (performed 
at least within 1 year of breath test and other investigations); ultrasound, transient elastography 
(Fibroscan®, Echosens, France), and/or Acoustic Radiation Force Impulse (AFRI) using 
Siemens ultrasound system (Siemens AG, Erlangen, Germany) and serum hyaluronic acid 
measured using a radiometric assay (Pharmacia, Uppsala, Sweden), performed within 6 months 
of breath test.  
NAFLD cirrhosis was diagnosed by liver biopsy in two participants, endoscopic features of 
portal hypertension in 12 participants and radiological features in one participant. 
Non-cirrhotic NAFLD was diagnosed by liver biopsy (in five participants) and the remaining 
nine participants were diagnosed by clinical and radiological features, non-invasive scores – such 
as Fibrosis -4 (Fib-4) score, aspartate aminotransferase to platelet ratio index (APRI), NAFLD 
fibrosis score and BARD, serum hyaluronic acid and transient elastography measurements[11-
14]. 
Greater diagnostic weight was given to histological or endoscopic diagnoses (in the case of 
cirrhosis); and in patients who had a definitive diagnosis of cirrhosis, the non-invasive markers 
were not considered. The healthy control group consisted of self-declared healthy participants. 
They were recruited through word-of-mouth and advertising posters in the institution. They 
were screened using questionnaire, physical examination, reported absence of any medical illness 
and use of any regular medication.   
Measures were taken to mitigate against the effect of dietary, environmental and medication. All 
participants attended a single study visit at Edinburgh Clinical Research Facility after an 
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overnight fast. Written informed consent was taken from all participants. Although no strict diet 
was enforced, both overnight fasting and careful oral hygiene with unchlorinated water 
preparation was undertaken. Participants refrained from using any perfumes or deodorants on 
the day of the visit. Smoking and alcohol consumption were restricted for 48 hours. 
Reconciliation of concomitant medication was ascertained at screening. Drugs were categorised 
as inducers, inhibitors and substrates[15]. Participants taking enzyme inducing drugs were 
excluded. A dedicated room was used for breath sample collection. Only the participant and the 
investigator were allowed to enter the room for the purpose of breath collection. Upon breath 
collection, the room was again secured. The interval between two consecutive subjects was at 
least 4 hours. 
Anthropometric measurement and venous sample collection were completed prior to the breath 
sample collection. Central obesity was defined as waist circumference of >94 cm for men and 
>78 cm for women taken midway between the lowest rib and the iliac crest[16]. Homeostatic 
Model Assessment (HOMA) was performed in participants without a known diagnosis of 
diabetes.[17]  
 
Exhaled breath collection 
Participants were given chlorinated water to rinse their mouth before breathing through a 
mouthpiece with their nose clipped into a 2-way non-rebreathing valve (Hans Rudolph 1410, 
Hans Rudolph, Kansas City, USA) with an inspiratory VOC filter (A2, North Safety, 
Middelburg, NL) and an expiratory silica reservoir to dry the expired air. The breathing 
manoeuvres have been previously described[18].  After 5 minutes of equilibration by tidal 
breathing with VOC-filtered air, the expiratory port was connected to a 10 L Tedlar sampling 
bag (SKC Inc., PA, USA). Participants then performed an inspiratory capacity manoeuvre and 
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exhaled the full expiratory vital capacity into the bag with an expiratory resistance of 20 cmH2O 
to close the soft palate and to obtain an expiratory flow of 0.1 to 0.2 L/s. 
The sampling method for VOCs has been described previously[18-21]. This sampling procedure 
incorporates inspiratory VOC filtering to minimise any external influence on the VOCs[22]. The 
combination of targeted analyses concerning 19 VOCs and additional stable factor of a dedicated 
climate-controlled room, reduces the change of a false discovery dramatically. Every conceivable 
effort was undertaken to minimise contamination and external influence. 
We did not capture consecutive breath samples for the same group of participants to monitor 
variation in VOCs over time, however authors have previously studied variations within a study 
group and found little variation[23]. 
 
Gas Chromatography and Mass Spectrometry (GC-MS) sample analysis 
GC-MS analysis was performed as previously described[22].  Briefly, the content of the Tedlar 
bags were transferred into stainless-steel adsorption tubes (Gerstel Steel Tenax® GR Sorbent 
Tubes, closed by Teflon Ferrules and Swagelok Stainless Steel Tube Caps, Philips, Eindhoven, 
The Netherlands) by a peristaltic pump (flow rate of 200 mL/min) within 30 min of collection. 
Adsorption tubes were stored in an airtight package at 4oC and transported to Philips Innovation 
Services (Eindhoven, The Netherlands) for analysis using methodology previously described[20] 
(Supplementary data). 
 
 GC-MS Quality Control (QC) 
The GCMS was performed by an established commercial laboratory 
(https://www.philips.com/a-w/research/locations/eindhoven.html) with a strong reputation in 
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Europe as a reference measurement centre. Accordingly, our commercial collaborators 
confirmed through their internal analyses and QC, that the signals had not changed within 28 
days of storage. Furthermore, they also confirmed that there was negligible background signal 
from the Tedlar bags (it can add N,N-dimethylacetamide and phenol to the breath signal). After 
receipt of the Tenax tubes, the tubes were dried and stored in the fridge until analysis. 
 
Chemical Identification 
Owing to the complex nature of untargeted GC-MS data we performed a semi-targeted non-
quantitative ubiquity analysis of VOCs in the study groups of 19 VOCs. This set of 19 
compounds were selected based on previous supportive literature and biological plausibility in 
our study population. The studied VOCs and IUPAC (International Union of Pure and Applied 
Chemistry) are thus listed: butane, 2-butanone, 3-methylpentane, octane, styrene, decane, 
acetone, isoprene, dimethyl sulfide, cyclopentane, methyl vinyl ketone (3-buten-2-one), dimethyl 
sulfoxide, benzaldehyde, phenol (hydroxybenzene), D-limonene, acetophenone, undecane (n-
undecane), tetradecane and alfa-terpinene (terpinene).  
We used Xcalibur version 3.0 (Thermo Fisher Scientific, MA, USA) to assess the data. Files were 
converted to .raw files. Reconstructed ion chromatograms of each of the 19 compounds were 
generated. The mass spectra of each discernible peak were assessed using the National Institute 
of Science and Technology (NIST) library database in the Thermo Library manager section of 
Xcalibur 3.0. The putative chemical identity was determined by examining representative mass 
spectral data and m/z ion patterns. A match with a probability greater than 80% according to the 
NIST library was used to confirm the compound. This was further confirmed using AMDIS 
freeware (Automated Mass Spectral Deconvolutional & Identification System, 
http://www.amdis.net/index.html).  
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In our experience general automated peak picking is much faster than manual peak selection and 
integration, especially for large data sets. Our previous published work has been performed using 
this technique, where all data analysis was done automatically, but tailored to the specific data[21, 
24].  
These compounds have been previously shown to be associated with cirrhosis[6],[8]. Within the 
samples we identified these compounds based on the mass spectra and an identifiable peak at 
consistent retention time. The peak of the extracted ion chromatograms of each compound were 
integrated using Xcalibur 3.0 (Thermo Fisher Scientific, USA). The peak was recorded as not 
detected if the ion count was below 500 ion counts at the assigned retention time. All compound 
peak areas were normalised to the peak area of toluene-d8 in each sample, as this was added to 
all samples when analysed by GC-MS as an internal standard.  
 
Statistical analysis 
Statistical analyses were performed using IBM SPSS Statistics for Macintosh version 21.0 (IBM 
Corp., Armonk, NY) and GraphPad Prism version 5.0a (SanDiego, CA, USA). Data were 
presented as mean (standard deviation (SD)) or median (interquartile range (IQR)) for 
continuous variables. Categorical variables were presented as frequency and percentage. Data 
were analysed using ANOVA with Bonferroni correction to minimize false discovery. 
Multivariable logistic regression analysis was performed to build a model for prediction of 
cirrhosis and non-cirrhotic liver disease; all breath compounds were considered for inclusion. 
Discrimination was used for internal model validation; measuring the ability to rank patients by 
risk of cirrhosis such that patients with a higher predicted risk are more likely to have cirrhosis. 
Discrimination was measured by the Area Under the Receiver Operating Characteristics curve 
(AUROC). All individual compounds with AUROCs of 0.80 or above were further assessed to 
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find the combination of any two that provided the highest AUROC. After choosing the final 
model, Harrell’s method was used to compute the validation metric with over-fitting bias 
correction through bootstrap resampling[25]. A thousand bootstrap samples (B = 1,000) were 
drawn from the original data set and a new model with the same model settings was built on 
each bootstrap resample. Prediction on patients that were not chosen in the resample was 
calculated. An optimism factor was calculated over the 1,000 new models and the bias-corrected 
validation metric was obtained by subtracting this optimism value from the AUROC directly 
measured from the original model. Bonferroni correction was applied to decrease the false 
discovery rate and a p value <0.01 was considered significant. AUROC curves were used to 
calculate the performance of diagnostic tests and for calculating the best point of separation 
between sensitivity and specificity. Given the sample size and to reduce any possibility of beta 
error, a p-value lower than 0.01 was considered significant and clinically valuable. 
 
Ethics permission 
The clinical study was conducted according to the ethical principles of the Declaration of 
Helsinki 2013 and following approval from the East of Scotland Research Ethics Committee 
(REC reference: 15/ES/0207) and the NHS Lothian Research and Development department 
(Ref: E151593).  
 
RESULTS 
Baseline characteristics 
Baseline characteristics of the study population are summarised in Table 1. Two samples (one 
non-cirrhotic NAFLD and one healthy control participant) had to be excluded for technical 
reasons. Participants in the healthy control group were significantly younger (median 39 (IQR 
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20-59) years) than those with NAFLD without cirrhosis (median 60 (IQR 29-75) years) or with 
cirrhosis (median 69 (IQR 44 -76) years). Similarly, BMI and waist circumference were lower in 
healthy controls compared with those with NAFLD.  
Among participants with NAFLD cirrhosis, 80% had endoscopic evidence of portal 
hypertension (six (40%) varices, four (27%) portal hypertensive gastropathy (PHG) and one 
(6%) each for gastric antral vascular ectasia (GAVE) and dilated azygous vein on endoscopic 
ultrasound). Of the remaining four (20%) who did not have endoscopic evidence of portal 
hypertension, two had coarse liver echotexture with splenomegaly on ultrasound and two had 
coarse liver echotexture alone. 
 
Quantification of exhaled VOCs in the study population 
Of the 19 VOCs studied in the exhaled breath samples, seven compounds (styrene, acetone, 
isoprene, DMS, D-limonene, acetophenone and terpinene) were significantly different between 
the groups (Figure 1). There was no correlation between age and VOCs in line with previous 
findings[7, 8, 26]. However, acetone, isoprene, DMS and D-limonene were correlated with BMI. 
Given the lower BMI in the control group than those with NAFLD, and because some 
compounds such as breath acetone have been shown to correlate with body weight, we adjusted 
each compound for BMI[27]. This was achieved by dividing the intensity of VOC by the 
corresponding BMI, before the inclusion into the statistical modelling[27]. Significant differences 
persisted between the cirrhotic and healthy control groups for styrene, acetone, isoprene, DMS, 
D-limonene, acetophenone and terpinene. Isoprene is a by-product of cholesterol biosynthesis. 
However, similar to other authors, we found no correlation between the serum cholesterol and 
isoprene (rho=0.87 (-0.32, 0.48) p=0.654)[3]. 
In our study, D-limonene was inversely correlated with serum albumin (Pearson’s r=0.7, 
p<0.001). In contrast, APRI score correlated positively with D-limonene (Pearson’s r=0.6, 
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p<0.01). No significant correlation was found between the detected VOCs and serum hyaluronic 
acid or transient elastography data (data not shown). 
Effect of diabetes on VOCs production  
In the cirrhotic group, 13 participants (87%) had Type 2 diabetes mellitus with HbA1c (IFCC) 
ranging between 44 mmol/mol to 103 mmol/mol measured within 3 months of breath 
sampling. Two participants had insulin resistance as evidenced by HOMA-IR score (2.7 and 6.2). 
In the non-cirrhotic NAFLD group, eight participants (57%) had Type 2 diabetes mellitus with 
HbA1c (IFCC) ranging between 45 mmol/mol to 94 mmol/mol and six (43%) participants had 
insulin resistance with HOMA-IR ranging between 1.7 to 6.9. It is conceivable that insulin 
resistance and/or Type 2 diabetes had contributed to the high level of acetone, particularly in the 
cirrhotic group. We also noted that the actual differences in breath acetone were probably bigger 
than measured here since the concentration of acetone recorded was outside the linear range of 
the instrument.  
 
Differentiating patients with non-cirrhotic NAFLD from healthy control participants 
Levels of isoprene, acetophenone, and terpinene were significantly lower in non-cirrhotic 
NAFLD patients than in healthy controls. Of these, terpinene had the highest AUROC for 
predicting non-cirrhotic NAFLD (0.84 (95% CI 0.68 – 0.99, p=0.002)) (Table 2 and Figure 2). 
Combining terpinene with isoprene and/or acetophenone did not improve the diagnostic 
accuracy. 
 
Differentiating patients with NAFLD cirrhosis from healthy control participants 
Levels of styrene, isoprene, acetophenone and terpinene were significantly lower in participants 
with NAFLD cirrhosis compared with healthy individuals. In contrast, levels of DMS and D-
limonene were significantly higher in patients with NAFLD cirrhosis compared with healthy 
 13
controls. DMS and D-limonene had the highest predictive accuracy for predicting NAFLD 
cirrhosis with AUROCs of 0.94 (95% CI 0.86 – 1.00, p<0.001) and 0.91 (95% CI 0.79 – 1.00, 
p<0.001), respectively (Table 3). However, combining DMS and D-limonene had even higher 
predictive accuracy for diagnosing NAFLD cirrhosis with AUROC of 0.98 (95%CI 0.93 – 1.00, 
p<0.001) (Figure 3). 
 
 
Differentiating patients with non-cirrhotic NAFLD from NAFLD cirrhosis 
Levels of DMS and D-limonene were significantly higher in patients with NAFLD cirrhosis 
compared with non-cirrhotic NAFLD. DMS and D-limonene had the highest predictive 
accuracy for NAFLD cirrhosis with AUROCs of 0.88 (95% CI 0.74 – 1.00, p<0.001) and 0.83 
(95% CI 0.68 – 0.98, p=<0.002), respectively (Table 4). However, combining DMS and D-
limonene had even higher predictive accuracy for diagnosing NAFLD cirrhosis with AUROC of 
0.91 (95%CI 0.82 – 1.00, p<0.001) (Figure 4). 
 
DISCUSSION 
In this pilot study, we examined the concentration of VOCs in exhaled breath in adult NAFLD 
patients with cirrhosis and non-cirrhotic NAFLD. We highlighted three compounds (acetone, 
DMS and D-limonene) that differentiated between cirrhosis and healthy controls. More 
importantly, we have shown that DMS and D-limonene can discriminate between NAFLD 
patients with and without cirrhosis.  From a clinical standpoint, the findings are important as 
these compounds can potentially serve as biomarkers for the stratification of NAFLD.   
There have been previous studies that have shown differences in VOC concentrations between 
chronic liver disease and healthy liver[6, 8]. These differences were identified using GC-MS in 
patients with liver disease of various aetiologies. In our study, we focused solely on patients with 
NAFLD. Furthermore, we have adjusted the measured VOC to BMI to provide a more accurate 
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reflection of the metabolic profile as acetone, breath isoprene, 1-decene, 1-octene, ammonia and 
hydrogen sulfide have been found to be influenced by body weight[27]. 
Changes in cellular metabolism, insulin resistance and oxidative stress in NAFLD are dynamic 
processes. It is possible that there is a distinct VOC profile for the stages of NAFLD and that 
the pattern is influenced by a complex interaction between oxidative stress, mitochondrial 
impairment and metabolic pathways. Additionally, the onset of fibrosis can limit the capacity of 
metabolic and degradation pathways, which can potentially affect VOCs. It is also noteworthy 
that as NAFLD progresses, the presence of mitochondrial impairment can limit oxidative 
capacity thus promoting the diversion of acetyl-CoA towards non-oxidative pathways including 
ketogenesis - hence the higher formation of acetone in cirrhosis[28, 29]. This could also explain 
lower levels of isoprene in advanced liver disease. 
Ketogenesis and levels of acetone can also be induced by fasting. In our study, breath sampling 
was obtained from all participants after overnight fasting to minimise the known physiological 
effects of food intake on exhaled VOC concentrations. Although fasting may have influenced 
the overall levels of acetone, we have shown that the levels of acetone are substantially higher in 
cirrhotic patients than in healthy controls. Furthermore, our finding is consistent with previous 
studies[8, 30] 
  
Similarly, a higher concentration of D-limonene in NAFLD cirrhosis could either reflect 
inefficient metabolism (reduced levels of Cytochrome P450 enzymes - CYP2C9 and CYP2C19) 
that results in bioaccumulation or represent an adaptation to insulin resistance[6, 7, 26, 31]. D-
limonene is a monoterpene that has been shown to have an antidiabetic effect and modulates 
lipid metabolism[32, 33]. Although elevated D-limonene levels has previously been reported in 
the context of cirrhosis, our study is first to confirm its presence in exhaled breath in the context 
of NAFLD cirrhosis[6, 8, 26],28.  D-limonene is also a major constituent in citrus essential oil, 
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which is used in various foods as a flavouring agent. Although food diary was not recorded in 
the present study, we applied strict environmental and participant preparation measures to 
minimise dietary influence or any other contamination. Additionally, previous work did not find 
any correlation between diet and breath limonene concentration[26]. Therefore, taken together, 
this suggests that our findings are specific for liver disease. 
It has long been considered that methyl-mercaptans and DMS are responsible for fetor hepaticus. 
DMS, being a derivative of methanethiol, has also been implicated in hepatic 
encephalopathy[34].  DMS breath levels are elevated in cirrhosis and correlate with the degree of 
porto-systemic shunting[34-36]. Our findings support this notion as 80% of the participants with 
NAFLD cirrhosis in our study had signs of portal hypertension on gastroscopy. All of the 
cirrhotic participants were Child-Pugh Class A without clinical signs of encephalopathy. We 
speculate that a probable source of DMS is microbiota as previous studies have linked this to 
oral as well as gut dysbiosis[37, 38]. Methanethiol may be converted to hydrogen sulfide and 
oxidized to sulphate for detoxification which can be utiltised by sulphate-reducing bacteria; a 
process predominantly occurring in caecal tissue[39]. Pyrosequencing or next-generation 
sequencing studies to establish an association of VOCs with microbiota would require a higher 
number of well-characterised participants with a specific preparation. This is beyond the scope 
of our present feasibility study.  
 
Another abundant isomeric monoterpene detected in the exhaled breath in our study was 
terpinene. Consistent with previous studies, terpinene was able to discriminate cirrhosis and non-
cirrhotic NAFLD from healthy controls [7]. There is very little in the published literature about 
terpinenes and their role in the NAFLD pathophysiology is unknown. Terpinenes have been 
implicated in the oxidative stress pathways[40]. Thus, it is possible that the differences in the 
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levels of alpha-terpinene between healthy and NAFLD participants reflect the presence of 
oxidative stress in NAFLD.  
Whilst we cannot totally exclude the possibility that medications may have influenced the breath 
concentrations of terpinenes, we mitigated this through medication reconciliation at screening. 
We speculate from the outset that Cytochrome (CYP) activity would be impaired and drug 
metabolism (and interactions) would be complex. Therefore, attempts were made to maintain 
homogeneity of medication use in our participants by careful selection. Drugs were categorised 
either as ‘inducers’, ‘inhibitors’ or ‘substrates’ as previously described. None of the participants 
were on enzyme inducers or inhibitors. Therefore, it is unlikely that any of concomitant 
medications used by the participants could have influenced the terpenes, either directly or 
indirectly.  
 
There were some limitations to our study. Firstly, the participants were primarily selected based 
on clinical characterisation rather than exclusively on histological criteria, as this was a pragmatic 
observational pilot study. As such, it is likely that the non-cirrhotic NAFLD group consisted of 
participants with a variable degree of disease activity and fibrosis. NAFLD is a dynamic process 
and compensated advanced chronic liver disease (cACLD) is a continuum. The mean annual 
fibrosis progression rate in patients with NASH is 0.14 stages, compared with 0.07 stages in 
patients with NAFLD[41]. Therefore, although our study groups were as well characterised as 
possible, it is feasible that there was some overlap between participants with Childs A cirrhosis 
and participants with advanced fibrosis in the non-cirrhotic group. Similarly, healthy controls in 
our study did not undergo clinical phenotyping. It is conceivable that some of the participants in 
this group may have hepatic steatosis or even NASH [42]. The small sample size and case 
selection limitations mean that the findings may not be generalisable to the wider NAFLD 
population.  
 
 17
Secondly, although the participants underwent an overnight fast, the potential impact of diet and 
dietary preferences on the breath VOCs cannot be completely excluded. Thirdly, our data are 
cross-sectional and derived from a single-centre. Our findings will require further validation in 
external (longitudinal) cohorts of NAFLD patients. Finally, we have performed semi-targeted 
analysis rather than untargeted, thus, selection bias cannot be completely excluded. However, 
there is a risk in ‘omics data that the lowest responders are lost as the sensitivity of untargeted 
analysis is not the strength of the technique. Our approach therefore was to principally focus on 
specific compounds, and we interrogated 19 different compounds that have previously been 
described in the literature as having an association with liver disease. However, as we studied a 
semi-targeted analysis of VOCs in the context of NAFLD, it is possible that some VOCs with a 
pathogenic role in the NAFLD may have been missed in our analysis.  
 
We intentionally did not study alcoholic liver disease as the pathogenesis and the difference in 
the impact of metabolic dysregulation would have introduced a substantial heterogeneity. 
However, it would be interesting to compare the VOC profiles of the two aetiologies to identify 
novel (and possibly shared) pathogenetic mechanisms, as indicated by intriguing observations in 
a murine NAFLD model[10]. 
In conclusion, our study shows that breath VOCs can be a potential non-invasive diagnostic tool 
in NAFLD. We have shown that VOCs such as DMS and D-limonene can differentiate NAFLD 
cirrhosis from healthy liver. Furthermore, isoprene and terpinene concentrations can distinguish 
between NAFLD patients with and without cirrhosis. Correlation of VOCs with histological 
stages of liver disease is now required, which can facilitate non-invasive stratification of NAFLD.  
It will also be of interest to perform a larger study to determine the contribution of portal 
hypertension to VOCs production. Through our pilot study, we highlight potential biomarkers 
which now require further external validation in larger populations of NAFLD patients with 
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histologically defined disease. In addition, a parallel study of VOCs and gut microbiome profiling 
can provide further mechanistic insights. The emerging artificial intelligence methodology with 
sophisticated algorithms may also generate new stage-specific breath signatures for diagnosis and 
monitoring of disease progression in NAFLD. 
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Characteristics NAFLD cirrhosis 
(n=15) 
Non-cirrhotic 
NAFLD (n=14) 
Healthy controls        
(n=14) 
p-value 
Women (%) 4 (27) 5 (36) 9 (64) 0.70 
Age 69 (44 -76) 60 (29 -75) 39 (20-59) <0.001*** 
Height (meters) 1.73 (1.56 -1.81) 1.72 (1.50 -1.87) 1.72 (1.54 -1.84) 0.93 
Weight (kilograms) 96.4 (76 -118) 103.8 (73.4 -126.8) 61.45 (48.7 -74.7) <0.001*** 
BMI (kg/m2) 34.2 (25.4 – 37.8) 35 (30.9 – 39.8) 21.6 (18.6 – 24.7) <0.001*** 
Waist circumference (cm) 
Women 
Men 
 
110 (100 – 119) 
110 (96 -130) 
 
106 (95 – 126) 
110 (106 -136) 
 
74 (64.5 – 80) 
80 (73 – 85) 
<0.001*** 
Smoking status (%) 
Current smoker 
Ex-smoker 
Non-smoker 
 
1 (7) 
5 (33) 
9 (60) 
 
2 (14) 
2 (14) 
10 (72) 
 
1 (7) 
0 (0) 
13 (93) 
0.16 
Alcohol (units/week) 0 (0 – 10) 1 (0-7) 2.5 (0-10) 0.20 
Coffee consumption(cups/day) 3 (0-7) 2 (0 -7) 2 (0-4) 0.15 
Modality of diagnosis 
     Histology 
     Non-invasive 
      Elastography 
         TE 
        ARFI 
    Hyaluronic acid (µg/L) 
    Fibrosis score 
         APRI score 
         NAFLD fibrosis score 
         Fib-4 score 
         BARD Score 
 
2 (13) 
13 (87) 
 
17 (8.6) † 
3.2 (1.3) ‡ 
200 (241) ± 
 
0.42 (0.33) 
1.54 (1.17) 
2.31 (1.15) 
4 (1) 
 
5 (35) 
9 (65) 
 
8.9 (5.1) 
- 
40 (30) 
 
0.24 (0.15) 
-0.38 (1.66) 
1.39 (0.77) 
3 (3) 
 
 
 
 
- 
- 
- 
0.16 
 
 
 
<0.001*** 
 
<0.001*** 
 
0.007** 
0.017** 
0.004** 
0.082 
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Laboratory parameters 
HbA1c (IFCC) 
HOMA 
GGT (U/L) 
Albumin (g/L) 
AST (U/L) 
ALT (U/L) 
Platelets (109/L) 
 
54 (36 – 103) 
 4.45 (2.7 -6.2) ˆ 
147 (44 -843) 
36 (31 - 40) 
32 (25 -71) 
55 (14 – 69) 
210 (61- 271) 
 
49 (32 - 94) 
5.35 (1.7 -6.9) ˆˆ 
61 (22 -387) 
39 (35 - 44) 
27 (21 -78) 
44 (16 -115) 
229 (108 -289) 
 
- 
- 
- 
- 
- 
- 
- 
 
1.00 
0.91 
0.07 
 0.02** 
0.27 
0.14 
0.14 
Table 1: Baseline characteristics of study participants. Data presented as median and IQR or frequency (n) and 
percentage where appropriate. NAFLD, non-alcoholic fatty liver disease; BMI, body mass index; TE, transient 
elastography; ARFI, acoustic radiation force impulse; IFCC, International Federation of Clinical Chemistry); 
HOMA, Homeostatic Model Assessment; GGT, gamma-glutamyl transpeptidase; AST, aspartate aminotransferase; 
ALT, alanine aminotransaminase, † (n=10); ‡(n=3); ±(n=13), ˆ(n=2); ˆˆ(n=6) 
 
Figure 1: Levels of volatile organic compounds in exhaled breath in study participants. Healthy (healthy controls; 
n=14), non-cirrhotic NAFLD (NC NAFLD; n=14) and NAFLD cirrhosis (NAFLD C; n=15). Levels are adjusted 
for a unit toluene-d8 (internal standard reference) and body-mass index (BMI). Data expressed as mean with 
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standard error of mean. One-way analysis of variance (ANOVA) is performed with post-test Bonferroni correction. 
Significance is denoted as p<0.05 *, p<0.01** p<0.001*** 
 
Figure 2. Receiver operating characteristic (ROC) curve for breath terpinene in classifying patients with non-
cirrhotic NAFLD versus healthy participants. AUC, area under the ROC curve; NAFLD, non-alcoholic fatty liver 
disease; CI, confidence interval.  
 
 
 
 
 
 
 
Volatile organic compounds AUROC (95% 
confidence interval) 
p-value 
isoprene 0.75 (0.57 – 0.94) 0.022 
acetophenone 0.80 (0.63 – 0.97) 0.007 
terpinene 0.84 (0.68 -0.99) 0.002** 
 
Table 2: Area under receiver operating curves for different volatile organic compounds in classifying patients with 
non-cirrhotic NAFLD versus healthy participants. AUROC, area under receiver operating characteristic. 
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Figure 3. Receiver operating characteristic curve for a combination of D-limonene and dimethyl sulfide in 
classifying patients with NAFLD cirrhosis (n=15) versus control subjects (n=14). AUC, area under the ROC curve; 
NAFLD, non-alcoholic fatty liver disease; CI, confidence interval.  
 
 
 
 
 
 
Volatile organic compounds AUROC (95% 
confidence interval) 
p-value 
styrene 0.37 (0.16 -0.58) 0.239 
acetone 0.77 (0.58 -0.95) 0.015 
isoprene 0.49 (0.27 – 0.72) 0.965 
Dimethyl sulfide 0.94 (0.86 -1.00) <0.001*** 
D-limonene 0.91 (0.79 -1.00)  0.002*** 
acetophenone 0.40 (0.12 – 0.61) 0.36 
terpinene 0.34 (0.13 -0.54) 0.13 
  
Table 3: Area under receiver operating curves for different volatile organic compounds to in classifying patients with 
NAFLD cirrhosis versus control subjects. AUROC, area under receiver operating characteristic. 
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Figure 4: Receiver operating characteristic curve for a combination of D-limonene and dimethyl sulfide in 
classifying patients with NAFLD cirrhosis versus non-cirrhotic NAFLD. AUC, area under the ROC curve; 
NAFLD, non-alcoholic fatty liver disease; CI, confidence interval.  
 
 
 
 
 
Volatile organic compounds AUROC (95% 
confidence interval) 
p-value 
Dimethyl sulfide 0.87 (0.74 -1.00) <0.001*** 
D-limonene 0.83 (0.68 -0.98)  0.002** 
acetone 0.81 (0.63 -0.99) 0.005 
 
Table 4: Area under receiver operating curves for different volatile organic compounds for classifying patients with 
NAFLD cirrhosis versus differentiate NAFLD cirrhosis from non-cirrhotic NAFLD. AUROC, area under receiver 
operating characteristic. 
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Highlights 
 
 
• Metabolic dysfunction in liver disease is reflected in the bio-composition of exhaled 
breath 
• Specific volatile organic compounds can be measured in breath samples (volatomics) and 
have diagnostic potential in chronic liver disease 
• Levels of alfa-terpinene, dimethyl sulfide and D-limonene in exhaled breath may be used 
to stratify patients with non-alcoholic fatty liver disease 
 
